CMBA
NVO

C.M. Bidwell & Associates’s Novo Nordisk NVO Stock Holding History

C.M. Bidwell & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-926
Closed -$110K – 522
2024
Q3 		$110K Hold
926
– – 0.07% 163
2024
Q2 		$132K Buy
+926
New +$123K 0.09% 154
2017
Q4 		– Sell
-15,860
Closed -$382K – 429
2017
Q3 		$382K Buy
+15,860
New +$358K 0.59% 55
2014
Q3 		– Sell
-300
Closed -$7K – 273
2014
Q2 		$7K Buy
+300
New +$6.62K ﹤0.01% 226

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

C.M. Bidwell & Associates's NVO Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 926 shares — an estimated $110K sold.

C.M. Bidwell & Associates first reported a position in NVO in Q2 2014 and held it in 4 quarters. The position peaked at $382K in Q3 2017. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • C.M. Bidwell & Associates reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 926 Novo Nordisk shares in Q4 2024, an estimated $110K.
  • C.M. Bidwell & Associates first reported a position in Novo Nordisk in Q2 2014 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Novo Nordisk position peaked at $382K in Q3 2017.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.